Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 9, 2007, Pages 1396-1405

  García Velloso, María José ^a   Jurado, Matías ^a   Ceamanos, Carolina ^a   Aramendía, José Manuel ^a   Garrastachu, María Puy ^a   López García, Guillermo ^a   Richter, José Ángel ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Conventional imaging; Diagnosis; FDG PET; Recurrent ovarian cancer; Serum CA 125 levels

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18; PLATINUM DERIVATIVE;

ADULT; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RELAPSE; CONTRAST SENSITIVITY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG SENSITIVITY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; RADIODIAGNOSIS; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; CISPLATIN; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RECURRENCE; REPRODUCIBILITY OF RESULTS; WHOLE BODY IMAGING;

EID: 34548181591     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0366-9     Document Type: Article

References (33)

1. Boyle P, Leon ME, Maisonneuve P, Autier P. Cancer control in women. Update 2003. Int J Gynaecol Obstet 2003;83 Suppl 1:179-202.
2. Yancik R, Ries LG, Yates JW. Ovarian cancer in the elderly: an analysis of Surveillance, Epidemiology, and End Results Program data. Am J Obstet Gynecol 1986;154:639-47.
3. International Federation of Gynecology and Obstetrics. Annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet. 1989;28:189-90.
4. Hoskins WJ, Pérez CA, Young RC, editors. Epithelial ovarian cancer. Principles and practice of gynecologic oncology. Philadelphia: Lippincott; 1992.
5. Topuz E, Aydiner A, Saip P, Eralp Y, Tas F, Salihoglu Y, et al. Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer. Eur J Gynaecol Oncol 2000;21:599-602.
6. Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001;15:471-86.
7. 18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993;51:175-81.
8. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994;53:331-8.
9. 18F-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer 1999;9:117-22.
10. Zimny M, Siggelkow W, Schroder W, Nowak B, Biemann S, Rath W, et al. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001;83:310-5.
11. Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging 2002;29:797-803.
12. 18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging 2004;31:196-201.
13. 18F]-fluoride. Appl Radiat Isot 1990;41:49-55.
14. Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993;71:517-23.
15. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9:1138-50.
16. 18F-fluoro-2- deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker. Neoplasma 2002;49:329-33.
17. Rustin GJ, Nelstrop AE, Bentzen SM, Bond SJ, McClean P. Selection of active drugs for ovarian cancer based on CA125 and standard response rates in phase II trials. J Clin Oncol 2000;18:1733-9.
18. Geary M, Foley M, Lenehan P. Recurrent ovarian carcinoma diagnosis and second-line therapy. Ir Med J 1995;88:698-700.
19. Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003;90:519-28.
20. Tay EH, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 2002;99:1008-13.
21. Zang RY, Li ZT, Tang J, Cheng X, Cai SM, Zhang ZY, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 2004;100:1152-61.
22. Onda T, Yoshikawa H, Yasugi T, Yamada M, Matsumoto K, Taketani Y. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 2005;92:1026-32.
23. Garcia Velloso MJ, Boan Garcia JF, Villar Luque LM, Aramendia Beitia JM, Lopez Garcia G, Richter Echeverria JA. F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125. Rev Esp Med Nucl 2003;22:217-23.
24. Bristow RE, Giuntoli RL 2nd, Pannu HK, Schulick RD, Fishman EK, Wahl RL. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 2005;99:294-300.
25. 18FDG versus tecnicas complementarias de imagen. Rev Esp Med Nucl 2003;22:148.
26. Ruiz-Hernandez G, Delgado-Bolton RC, Fernandez-Perez C, Lapena-Gutierrez L, Carreras-Delgado JL. Meta-analysis of the diagnostic efficacy of FDG-PET in patients with suspected ovarian cancer recurrence. Rev Esp Med Nucl 2005;24:161-73.
27. Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 2001;176:1449-54.
28. 18F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels. Clin Positron Imaging 2000;3:231-6.
29. Townsend DW, Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol 2002;75:S24-30.
30. Pannu HK, Cohade C, Bristow RE, Fishman EK, Wahl RL. PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation. Abdom Imaging 2004;29:398-403.
31. Hauth EA, Antoch G, Stattaus J, Kuehl H, Veit P, Bockisch A, et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J Radiol 2005;56:263-8.
32. 18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur J Radiol 2000;10:761-7.
33. 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 2001;21:3691-4.